Comparison 1. Sorafenib versus Sunitinib.
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1.1 Progression‐free survival | 1 | Hazard Ratio (IV, Random, 95% CI) | Totals not selected | |
| 1.2 Overall survival | 1 | Hazard Ratio (IV, Random, 95% CI) | Totals not selected | |
| 1.3 Serious adverse events (Grade 3 or 4) | 1 | Risk Ratio (M‐H, Random, 95% CI) | Totals not selected | |
| 1.4 Response rate | 1 | Risk Ratio (M‐H, Random, 95% CI) | Totals not selected | |
| 1.5 Minor adverse events (Grade 1 or 2) | 1 | Risk Ratio (M‐H, Random, 95% CI) | Totals not selected |